Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RA~* Currently receiving an adequate dose of methotrexate (MTX) for treatment of RA~* Active RA at time of screening and baseline~Exclusion Criteria:~* Previous or current treatment with etanercept (ETN), other tumor necrosis factor-alpha inhibitors, or other biologic agents~* Concurrent treatment with a DMARD, other than MTX, at screening~* Receipt of any DMARD, other than MTX, within 3 months before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Etanercept + Methotrexate
- 2 (Type: ACTIVE_COMPARATOR): DMARD therapy Methotrexate + Sulfasalazine/Hydroxychloroquine/Leflunomide

Based on this trial design, predict the completion outcome and termination type (if applicable).